All In Biotech

Drug Trial Radar · NCT02746796

Study of ONO-4538 in Gastric Cancer

ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer

Last checked: Nov 19, 2026Latest source record: May 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 680 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

680

Planned (sponsor's estimate)

Start

Mar 2016

Primary completion

Jan 2020

Study completion Nov 17, 2022

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of study is to evaluate the efficacy and safety of ONO-4538 with chemotherapy in unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) not previously treated with the first-line therapy. Part 1 is intended to evaluate the tolerability, safety, and efficacy of ONO-4538 in combination with SOX therapy (Tegafur / gimeracil / oteracil potassium + Oxaliplatin) or CapeOX therapy (Capecitabine + Oxaliplatin). In part 2, the investigator or the subinvestigator will choose a chemotherapy (SOX or CapeOX therapy), taking into account the condition of each subject. Part 2 is planned to evaluate the efficacy and safety of ONO-4538 + chemotherapy in comparison with placebo + chemotherapy.

Conditions

  • Gastric Cancer

Interventions

  • ONO-4538Drug

  • OxaliplatinDrug

  • Tegafur- Gimeracil-Oteracil potassiumDrug

  • CapecitabineDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (central assessment by IRRC) (only Part 2)Time frame: Up to study completion (estimated time frame: 48 months)
  2. Overall survival (only Part 2)Time frame: Up to study completion (estimated time frame: 54 months)

Locations

130 sites in 3 countries. Site status is shown where the registry gives one.

  • Akita Clinical Site

    Akita, Japan

  • Chiba Clinical Site1

    Chiba, Japan

  • Chiba Clinical Site2

    Chiba, Japan

  • Fukui Clinical Site

    Fukui, Japan

  • Fukuoka Clinical Site1

    Fukuoka, Japan

  • Fukuoka Clinical Site2

    Fukuoka, Japan

  • Fukuoka Clinical Site3

    Fukuoka, Japan

  • Fukuoka Clinical Site4

    Fukuoka, Japan

  • Fukushima Clinical Site

    Fukushima, Japan

  • Hiroshima Clinical Site1

    Hiroshima, Japan

  • Hiroshima Clinical Site2

    Hiroshima, Japan

  • Hiroshima Clinical Site3

    Hiroshima, Japan

  • Kumamoto Clinical Site1

    Kumamoto, Japan

  • Kumamoto Clinical Site2

    Kumamoto, Japan

  • Kumamoto Clinical Site3

    Kumamoto, Japan

  • Kyoto Clinical Site1

    Kyoto, Japan

  • Kyoto Clinical Site2

    Kyoto, Japan

  • Kyoto Clinical Site3

    Kyoto, Japan

  • Niigata Clinical Site

    Niigata, Japan

  • Okayama Clinical Site

    Okayama, Japan

  • Osaka Clinical Site1

    Osaka, Japan

  • Osaka Clinical Site2

    Osaka, Japan

  • Osaka Clinical Site3

    Osaka, Japan

  • Osaka Clinical Site4

    Osaka, Japan

  • Shizuoka Clinical Site

    Shizuoka, Japan

  • Tokushima Clinical Site

    Tokushima, Japan

  • Toyama Clinical Site

    Toyama, Japan

  • Wakayama Clinical Site

    Wakayama, Japan

  • Yamagata Clinical Site

    Yamagata, Japan

  • Aichi Clinical Site

    Nagoya, Aichi-ken, Japan

  • Aomori Clinical Site

    Hirosaki, Aomori, Japan

  • Aomori Clinical Site

    Misawa, Aomori, Japan

  • Chiba Clinical Site

    Funabashi, Chiba, Japan

  • Chiba Clinical Site

    Kamogawa, Chiba, Japan

  • Chiba Clinical Site

    Kashiwa, Chiba, Japan

  • Ehime Clinical Site1

    Matsuyama, Ehime, Japan

  • Ehime Clinical Site2

    Matsuyama, Ehime, Japan

  • Fukuoka Clinical Site

    Iizuka, Fukuoka, Japan

  • Fukuoka Clinical Site1

    Kitakyushu, Fukuoka, Japan

  • Fukuoka Clinical Site2

    Kitakyushu, Fukuoka, Japan

Showing 40 of 130 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.